EP0725830A1 - Expression de proteines leurres virales soumises a une region de regulation de locus et leurs utilisations - Google Patents

Expression de proteines leurres virales soumises a une region de regulation de locus et leurs utilisations

Info

Publication number
EP0725830A1
EP0725830A1 EP94927720A EP94927720A EP0725830A1 EP 0725830 A1 EP0725830 A1 EP 0725830A1 EP 94927720 A EP94927720 A EP 94927720A EP 94927720 A EP94927720 A EP 94927720A EP 0725830 A1 EP0725830 A1 EP 0725830A1
Authority
EP
European Patent Office
Prior art keywords
cell
nucleic acid
vector according
acid vector
recombinant nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94927720A
Other languages
German (de)
English (en)
Inventor
Roger Kingdon Craig
Franklin Gerardus Grosveld
Elaine Dzierzak
David Abraham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Therexsys Ltd
Original Assignee
Medical Research Council
Therexsys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council, Therexsys Ltd filed Critical Medical Research Council
Publication of EP0725830A1 publication Critical patent/EP0725830A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Definitions

  • the present invention relates to an agent for anti-viral therapy which possesses a protective effect when administered to healthy individuals.
  • the agent of the invention may be a mutant HIV gene product.
  • HIV Human immunodeficiency virus
  • AIDS human acquired immunodeficiency syndrome
  • Conventional therapeutic strategies have concentrated on antiviral drugs such as AZT and on the development of preventive vaccines.
  • antiviral drugs such as AZT
  • the intracellular immunisation approach (Baltimore, 1988) has lead to the development of molecular strategies for the inhibition of HIV replication (Mali et al . , 1989, Trono et al . , 1989, Sczakiel et al., 1991, Sullenger et al., 1990).
  • cytotoxic agents such as diphtheria toxin A or ricin A chain genes under the control of lens (Breitman et al., 1987; Landel et al . , 1988) or pituitary (Behringer et al . , 1988) specific promoters. After microinjection into mouse embryos and the production of transgenic animals, these constructs resulted in the destruction of either lens or pituitary cells.
  • these toxin genes are unsuitable for somatic therapy because of the constitutive cell lethality and the extreme sensitivity of mammalian cells to diphtheria and ricin toxins.
  • the Herpes Simplex Virus type 1 thymidine kinase (tk) gene product is a conditional cell lethal and has been shown to be toxic to mammalian cells only in the presence of nucleoside analogues such as acyclovir (ACV) or gancyclovir (GCV) . These analogues kill actively cycling cells because they possess high affinity for the tk gene product with little or no affinity for endogenous mammalian tk.
  • Another potential system for use in anti-HIV therapy involves the expression in cells susceptible to HIV infection of a decoy gene.
  • Decoy genes encode proteins which act as antagonists to natural proteins involved in the replication of the HIV virus.
  • a decoy gene may encode a defective mutant of a transactivator protein which is capable of binding to the transactivator-responsive site on the host or viral genome, yet is incapable of activating transcription.
  • Transdominant mutations have been reported in a number of viral transactivators which abolish or attenuate the ability of the wild-type protein to transactivate the target gene. Examples include transdominant mutations of E1A (Glen et al . , 1987), tax ( achsman et al . , 1987) and VM65 (Friedman et al . , 1988). Similar mutations in HIV genes have been described for the Tat transactivator (Pearson et al . , 1990) and the Rev transactivator (Bevac et al , 1992; Malim et al . , 1992) .
  • allelic variants of the HIV nef gene product have been shown to downregulate CD4 expression on thymocytes and to reduce the numbers of CD4 + thymocytes in transgenic mice (see our copending U.K. Patent Application No. 9305759.4 and Guy et al . , 1990).
  • Locus control regions are elements which confer position-independent, copy number-dependent expression of genes in gene transfer approaches. They have also been shown to permit high levels of expression of cloned genes and to possess tissue-specific properties. First discovered in globin genes (Grosveld et al, 1987) these elements are believed to direct the creation of independent regulatory domains within the chro atin structure of cell genomes, thereby ensuring the activity of a co-transferred gene.
  • LCRs other than those for globin genes have been described, for example in the CD2 gene in T-lymphocytes (Greaves et al . , 1989) and the lysozyme gene in macrophages (Bonifer et al . , 1990) and B-cells (see European patent application 460042) .
  • the targets of HIV infection are primarily CD4 + T- lymphocytes, but also include macrophages and, dendritic cells which are related to macrophages and of importance in initiating an immune response (reviewed in McCune, 1991) . These cells share very few common features except for being derived from common hematopoietic stem cells and susceptibility of HIV infection. Hematopoietic stem cells are not infected by HIV (Molina et al . , 1990; David et al . , 1991) .
  • a recombinant nucleic acid vector for the delivery of nucleic acid to a host organism comprising a transcription unit encoding a transdominant negative mutant of a viral gene product which has been selected substantially to avoid a negative biological effect under the control of a DNA sequence active in cells normally infected by a. virus which is effective to confer constitutive tissue-specific, integration site independent, copy-number dependent expression of the transcription unit.
  • substantially avoid a negative biological effect it is intended to denote that the decoy used in the present invention has been selected or specifically modified to give rise to a negligible adverse effect on host cells, which may safely be disregarded in therapeutic situations, or, preferably, no adverse effect at all.
  • the negative biological effect may be a biological impairment of cell function or the raising of a CTL response, as set out above, or both.
  • biological impairment of cell function it is intended to denote biological effects on host cells, such as downregulation of CD4, which may have a negative effect on the patient.
  • the host cells may be affected by the decoy in a manner similar to the pathologic activity of the virus.
  • the decoy proteins may have effects not normally associated with viral infection but which are undesirable when associated with a constitutively expressed foreign protein.
  • the decoy is selected to avoid, inter alia , an impairment of immune function in the host.
  • the invention comprises the constitutive expression of a Tat decoy.
  • the invention further provides the use of other natural decoy gene products which possess the desired characteristics displayed by tat, namely the absence of substantial negative biological effects.
  • the invention provides for the use of a decoy gene product which has been specifically mutated to reduce the incidence and strength of negative biological responses thereto. This may be achieved, for example, by mutation or deletion of certain domains of a decoy gene product. For example, the cell-impairing effects of a decoy gene product may be reduced or eliminated by the introduction of point mutations in the gene (see Guy et al . , 1990).
  • a mutated Tat gene product comprising a point mutation which abolishes its effector function, cytokine RNA levels are not affected, advantageously, therefore, a mutated Tat gene product is used in the present invention.
  • CTL response to a protein may be modified, either by the introduction of mutations at certain residues involved in binding to the presenting HLA molecules or interacting with the T-cell receptors (see Choppin et al . , 1992; 1991a, b;
  • the decoy of the invention may be mutated in accordance with naturally-derived HIV isolates which display a reduced CTL response.
  • the invention provides means to mutate- the decoy on an individual basis in order to reduce or eliminate the CTL response in that individual.
  • transdominant negative mutant it is intended to refer to a gene product which is rendered functionally transdominant over its viral analogue and is effective to block the activity of the viral analogue. Therefore, the term is to be interpreted functionally, and comprises mutants in the normal sense of the term, having an altered amino acid sequence, as well as mutants which are alternatively processed or spliced, and mutants which differ from the wild-type protein in patterns of expression.
  • the Nef gene product of HIV is known to be a transdominant inhibitor when expressed in excess. Therefore, an overproduced Nef protein is included in the term "transdominant negative mutant".
  • Constitutive expression confers a particular advantage of the invention, that is that the presence of the decoy in healthy cells effectively prevents the infecting virus from becoming established. If the decoy gene is only activated after infection by the virus, there is the possibility that the virus may become established before the decoy is able to exert any significant anti-viral effect
  • the DNA sequence controlling the transcription unit of the vector of the invention is preferably a Locus Control Region (LCR) .
  • LCR Locus Control Region
  • a number of LCRs have been described in the art and the selection of an appropriate LCR is within the capabilities of a person skilled in the art. In the case of the treatment of HIV infections, however, the use of the CD2 and the acrophage-specific lysozyme LCR is preferred. Both T-cells, in which the CD2 LCR is active, and macrophages are targets for HIV infection.
  • the vector of the invention is equipped with a promoter which is constitutively active in the target tissue type.
  • the CD2 promoter may be used.
  • the promoter may be active in cells other than the target tissue. In such a case, high-level expression in non-target cells is unlikely, because the LCR is inactive in these cells. Even if a certain amount of non-specific expression cells does occur, such expression will not be harmful as the gene product is selected to avoid negative biological effects. In any event, non-specific expression can be minimised by the use of efficient vector targeting techniques to deliver the vector of the invention.
  • the nucleic acid vector may be any vector capable of delivering nucleic acid to a cell.
  • the vector may be a plasmid, a virus or a linear DNA fragment.
  • the vector may be naked, complexed with proteins or packaged in a delivery system such as a liposome, virosome, or receptor mediated complex.
  • the vector of the invention is preferably for use in the transfection of stem cells. Therefrom stems a further advantage of the invention, that is that the decoy is expressed in all cells of a particular lineage.
  • the stem cells may be hematopoietic stem cells.
  • T-cells may be targeted directly.
  • the targeting of T-cells is desirable, for example, in the case where HIV infection is already established but the virus has not yet spread to the peripheral T-cell population. In this instance, such cells may be effectively protected from viral infection.
  • the host organism may be a mammal, insect, fish, plant or any other organism which it is desired to protect from viral disease.
  • the host organism is man.
  • the decoy may be prepared following any of the protocols known in the art. For example, the method of Pearson et al . (1990) may be used to generate deletion mutants of Tat which lack the transactivating function but retain the ability to bind to the tat region. Such deletion mutants may be tested for decoy activity as described in Pearson et al . or according to the methods set forth in our copending U.K. Patent Application No. 9305759.4 as well as International Patent Application WO90/14427.
  • the potential toxicity of any such mutants may be tested by the methods described hereinbelow. Should such mutants prove to give rise to a CTL response in a patient, they may be further mutated to reduce this response, in accordance methods known in the art.
  • the decoy gene may be derived from any virus which gives rise to infection in man or other organisms, including plants. Especially preferred, however, are HIV decoys such as Tat, Rev or Nef decoys.
  • the decoy may be derived from the same virus as it is intended to combat with the vector of the invention. However, it is envisaged that decoys derived from viruses other than one it is intended to treat may be used. For example, it has been noted that an HTLVl Rex decoy is active in suppressing HIV1 Rev function (Bohnlein et al . , 1991). Furthermore, it is envisaged that entirely artificial decoy genes encoding specialised decoy proteins may be designed. For example, an artificial decoy gene may be designed which encodes the tar-binding domain only of the HIV Tat transactivator, or an analogue of the tar-binding domain which effectively competes for tar binding with wild type Tat.
  • the vector of the invention is preferably for use in the transfection of a patient's cells in vivo or ex vivo , for the treatment of a viral disease. According to a second aspect of the invention, therefore, there is provided a vector according to the first aspect of the invention for use in therapy.
  • the vectors of the invention be used for the prophylaxis of viral infections because it is believed that it may be important to avoid establishment of the viral infection in the host. However, especially in the early stages of a viral infection, it is envisaged that the vectors of the invention may have a conventional therapeutic application effective to attenuate and eventually eliminate the viral infection.
  • the vector of the invention is used for the treatment of stem cells or T-cells ex vivo .
  • a vector according to the first aspect of the invention for use in the treatment of stem cells or T-cells ex vivo .
  • Stem cells or T-cells may be isolated according to procedures described in the prior art, as set out hereinbefore.
  • stem cells or T-cells may be targeted using an efficient targeted transfection technique, such as that described in our copending U.K. Patent Application No. 9317380.5. Using such a technique, it is possible to transfect stem cells or T- cells in whole blood obtained from patients with extremely high efficiency.
  • a method for treating or preventing a viral infection comprising the steps of:
  • the cell is a stem cell.
  • the cell is a haematopoietic stem cell.
  • the cell may be a T-cell.
  • Haematopoietic stem cells and T-cells are easily removed from the body of a patient, for example from cord blood, peripheral blood or bone marrow aspirate.
  • Transfection of stem cells may be accomplished by any of the protocols cited hereinbefore.
  • the transfected stem cells once returned to the body of the patient, will divide in the usual manner and populate the patient with cell lineages carrying the heterologous gene comprised in the vector of the invention.
  • the cell lineages thus derived will possess the antiviral capabilities conferred by the heterologous gene.
  • a vector according to the invention in the manufacture of a composition for use in the treatment or prophylaxis of a viral disease.
  • the composition comprises the vector of the invention in a suitable buffer for use in the transfection of cells either in vivo or ex vivo .
  • the buffer will consist essentially of pharmaceutically acceptable excipients, diluents or carriers.
  • the nature of the buffer will be determined by the transfection protocol being employed. For example, if the method described in our copending U.K. Patent Application No. 9317380.5 is to be used, the buffer as described therein is used.
  • a cell comprising a transcription unit encoded by the vector of the invention.
  • the cell is a stem cell and advantageously it is a haematopoietic stem cell.
  • the cell may be a T-cell.
  • the invention further provides a method for the treatment or prevention of a viral infection comprising administering to a patient a pharmaceutically effective amount of a composition comprising the vector of the invention in admixture with a pharmaceutically acceptable excipient, diluent or carrier.
  • Figure 1 is a diagrammatic representation of the structure of the CD2-Tat transgene
  • FIG. 1 shows the identification of the Tat DNA in transgenic mice carrying the CD2-Tat transgene
  • Figures 3 A and B show the identification of Tat RNA in transgenic mice carrying the CD2-Tat transgene
  • Figure 4 shows a FACS analysis of thymus tissue from transgenic and non-transgenic mice
  • Figure 5 shows a FACS analysis of spleen and lymph node tissues from transgenic and non-transgenic mice
  • Figure 6 shows the impact of the presence of the Tat transgene on cytokine gene expression in transgenic mice
  • Figure 7 is a slot blot showing the generation of transgenic mice carrying a mutated Tat transgene in which Tyr 47 has been mutated to Ala;
  • Figure 8 is a slot blot which demonstrates that mutant Tat has no effect on the expression of the TNF-3 gene.
  • a DNA fragment comprising the Tat coding sequence was ligated into a unique EcoRl site in the first exon of the CD2 gene in the p2629 CD2 expression plasmid, which was obtained from Dr. D. Kioussis, NIMR, Mill Hill, Great Britain.
  • a 4.5 kb fragment containing the CD2 LCR was isolated from p2694 (also obtained from Dr. Kioussis) and ligated into the unique Bam HI - Not 1 sites of p 2629.
  • the 12 kb Sal 1 - Not 1 fragment comprising the CD2-Tat construct was then excised and microinjected into single- cell mouse embryos as previously described (Grosveld et al . , 1987) . Positive founder animals were bred with CBA x C57 BL/10 mice and lines maintained as heterozygotes.
  • RNA was prepared using the lithium chloride/urea method (Fraser et al . , 1990).
  • For Northern blot analysis (Sambrook et al . , 1989) lO ⁇ g of RNA was run on a 1% formaldehyde gel, blotted onto nitrocellulose and probed with a 800 bp Ba HI- Smal nef fragment from pTG1147.
  • For RNA slot blots (Sambrook et al . , 1989) 5 ⁇ g of RNA was blotted onto nitrocellulose and probed as above.
  • RNA from the Nef producing CRIP L producer cell line (Schwartz et al . , 1992) was used as a positive control.
  • Exon 1 (encoding aa 1-72) of the HIV-1 TAT gene was inserted downstream of the transcriptional start site in the first exon of the human CD2 gene ( Figures 1 and 2) .
  • a stop codon was constructed in the sequence of human CD2 exon 2 so as to eliminate the production of CD2 prtein.
  • the human CD2 LCR element was ligated to the 3' end of the construct.
  • a Sall- Notl fragment was injected into fertilized mouse eggs. At lb
  • Line C (2 on figure 3A) contains 70 copies and line E (4 on figure 3A) contains 40 copies.
  • SI nuclease RNA protection was performed on various tissues from a transgenic ans a non-transgenic mouse using a TAT exon 1 probe. As shown in figure 3B only thymus expressed TAT highly. Spleen expressed Tat only to low levels. No expression was observed in the kidney or liver of the transgenic mouse or in any of the tissues of the control non-transgenic.
  • CD4 and CD8 T cells subsets are affected by the overexpression of HIV-TAT
  • antibody staining and FACS analysis was performed on thymocytes, spleen and lymph node cells from CD2-TAT transgenic mice ( Figures 4 and 5) .
  • Single cell suspensions were prepared from the tissues of line C and line E transgenic mice (samples 3 and 4 respectively) and their non-transgenic litter ates (samples 1 and 2) .
  • PE labeled CD8 and FITC labeled CD4 antibodies were incubated with the cells and FACS analysis performed. As shown in the contour plots, no changes in the percentage of double negative, double positive or single positive subsets were found in the thymus of transgenic mice.
  • TAT induced transcriptional upregulation of TNT-3 leads to overproduction of functional TNF-jS as measured by cytoxicity.
  • Cytokine gene expression is affected by the pressure of HIV- TAT.
  • RNA from CD2-TAT transgenic mice was prepared from thymocytes of line C transgenic mice (C+l and C+2) and a non-transgenic littermate (C-) and from thymocytes of line E transgenic mice (E+l and E+2) and a non-transgenic littermate (E-) .
  • 10 ⁇ g of RNA was loaded per lane on a formaldehye agarose gel.
  • RNA was transferred onto a filter and hybridizyed with a 3-actin probe as an RNA quantation control and a TAT probe for verification of transgene expression.
  • the filter was rehybridized several times with probes for cytokine genes TGF-/3, IL-4R, TNF-0 and TNF- ⁇ .
  • Autoradiagrams of the Northern blot demonstrate an increase in expression of TGF-3, IL-4R and TNF-/3 gene expression in the TAT transgenic mice.
  • hybridization signal with the TNF- ⁇ probe suggests no change or a decrease in TNF- ⁇ gene expression in the Tat positive mice.
  • TNF- ⁇ levels decrease by about 25%.
  • TAT in thymocytes has an effect on cytokine gene expression.
  • a 12kb Sall-NotI fragment containing the CD2 promoter and LCR element and exon 1 (encoding aal-72) of a mutant form of the HIV-1 TAT gene in which amino acid 47 had been converted from a tyrosine into an alanine (47 Tyr > Ala) was injected into fertilized mouse eggs.
  • three transgenic founders were created (Lines A6, A7 and A8) . In comparison with transgene copy number controls from 0 to 50 (Lane B) , these founders contained between 8 and 25 copies of the transgene.
  • thymocyte T cell subsets are affected by the expression of the mutant form of the HIV-TAT (47ala)
  • antibody staining and FACS analysis was performed on thymocytes from CD2-TAT (47ala) transgenic mice.
  • Single cell suspensions were prepared from mouse A6 and a non-transgenic animal, A4.
  • PE-labelled CD8 and FITC- labelled CD4 antibodies were incubated with the cells and FACS analysis was performed.
  • no changes were found in the total number of thymocytes derived from either transgenic or non-transgenic mice.
  • no difference was observed in the relative percentages of double negative (DN) , double positive (DP) , or single positive(SP) CD4 or CD8 cells in the thymus from the transgenic compared with the non-transgenic mouse.
  • RNA slot blot analysis was performed on RNA from CD2-TAT (47ala) transgenic mice to test for quantitative differences in cytokine gene expression (Figure 8) .
  • Total RNA was prepared from the thymoctes of CD2-TAT (47ala) transgenic mice A.6 and A.7, two non transgenic controls A.4 and A.5, and from two transgenic mice, one from line C(c.l) and one from line E(E.l) harbouring the wild type HIV-TAT.
  • Duplicated lO ⁇ g RNA samples were denatured and loaded onto the filter and hybridized wiht a 0-actin probe as an RNA quantitation control, and then with a probe specific for the cytokine TNF-/3.
  • RNA slot blot were qunatitated on a phosphorlmager and the fold changes in cytokine gene expression determined.
  • Table 3 when the signals are normalized against the internal quantitation control ⁇ - actin, although TNF-0 steady state mRNA was elevated in lines C and E, there was no increase in expression of this cytokine in the nutant HIV-TAT (47ala) transgenic mice. Thus, the expression of the mutant HIV-TAT (47ala) has no effect on TNF-3 cytokine expression.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un vecteur d'acide nucléique recombiné destiné à l'apport d'acide nucléique à un organisme hôte comprenant une unité de transcription codant un mutant négatif transdominant d'un produit génique viral choisi notamment pour éviter un effet biologique négatif chez l'hôte sous le contrôle d'une séquence d'ADN active dans des cellules normalement infectées par un virus, laquelle est efficace pour conférer une expression de l'unité de transcription qui soit spécifique aux tissus constitutifs, indépendante du site d'intégration et dépendante du nombre de copies.
EP94927720A 1993-09-24 1994-09-26 Expression de proteines leurres virales soumises a une region de regulation de locus et leurs utilisations Withdrawn EP0725830A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9319772 1993-09-24
GB939319772A GB9319772D0 (en) 1993-09-24 1993-09-24 Therapeutic agent
PCT/GB1994/002092 WO1995008635A1 (fr) 1993-09-24 1994-09-26 Expression de proteines leurres virales soumises a une region de regulation de locus et leurs utilisations

Publications (1)

Publication Number Publication Date
EP0725830A1 true EP0725830A1 (fr) 1996-08-14

Family

ID=10742498

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94927720A Withdrawn EP0725830A1 (fr) 1993-09-24 1994-09-26 Expression de proteines leurres virales soumises a une region de regulation de locus et leurs utilisations

Country Status (6)

Country Link
EP (1) EP0725830A1 (fr)
JP (1) JPH09505984A (fr)
AU (1) AU697095B2 (fr)
CA (1) CA2172073A1 (fr)
GB (1) GB9319772D0 (fr)
WO (1) WO1995008635A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2279675A1 (fr) 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Construits possedant certaines proprietes et/ou modifiant certaines proprietes pour localiser a l'interieur d'une cellule un construit d'acide eique pour utilisation therapeutique et de diagnostique
JP2000505802A (ja) * 1996-02-12 2000-05-16 コブラ セラピューティクス リミテッド ワクチン接種の新規な方法、ならびにそのための、第１のエピトープをコードする核酸および第２のエピトープを含有するペプチドを含むワクチン
US6689757B1 (en) 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
GB9609261D0 (en) * 1996-05-02 1996-07-03 Isis Innovation Gene expression in monocytes and microphages
CN104630149B (zh) * 2013-11-08 2018-08-21 中国科学院广州生物医药与健康研究院 外源线粒体导入到哺乳动物细胞中的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8718779D0 (en) * 1987-08-07 1987-09-16 Grosveld F G Dna sequence & expression vector
CA2074188C (fr) * 1990-01-18 2004-05-11 Julianna Lisziewicz Vecteur dote de multiples elements de reponse d'activation de la tat ayant un effet genique
GB9305761D0 (en) * 1993-03-19 1993-05-05 Medical Res Council Disease model
GB9305759D0 (en) * 1993-03-19 1993-05-05 Medical Research Council And T Hiv therapy method and agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9508635A1 *

Also Published As

Publication number Publication date
CA2172073A1 (fr) 1995-03-30
JPH09505984A (ja) 1997-06-17
GB9319772D0 (en) 1993-11-10
AU697095B2 (en) 1998-09-24
WO1995008635A1 (fr) 1995-03-30
AU7702694A (en) 1995-04-10

Similar Documents

Publication Publication Date Title
Cournoyer et al. Gene therapy of the immune system
EP0454781B1 (fr) Cellules de recombinaison pour des therapies d'infections et de troubles hyperproliferatifs et la preparation de ces cellules
US5837510A (en) Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders
EP0702084B1 (fr) Rétrovirus recombinants
JP4571306B2 (ja) ヌクレオチド配列の導入のためのトリプレックス構造のｄｎａ配列の利用
JPH10507061A (ja) アデノウイルス中にパッケージされたプラスミドｄｎａを用いる遺伝子送達ベクターおよびパッケージング細胞株
JPH04505261A (ja) ポルｉｉｉプロモーターの制御下の転写可能な外来ｄｎａを含む安定的に形質転換された真核細胞
AU696399B2 (en) Delivery system controlled through factors associated with HIV and cell
JP3908274B2 (ja) 遺伝子治療用の抗菌ペプチドをコードする治療用遺伝子を有するベクター
WO1992017211A1 (fr) Inhibition d'un retrovirus a l'aide d'acides nucleiques non codants s'hybridant sur des sequences d'encapsidation
AU697095B2 (en) Expression of viral decoy proteins under the control of a locus control region and uses thereof
Brady et al. Altered cytokine expression in T lymphocytes from human immunodeficiency virus Tat transgenic mice
JPH10510995A (ja) 胚細胞発現のためのレトロウイルスベクター
Amado et al. Gene therapy for the treatment of AIDS: animal models and human clinical experience
US6677311B1 (en) Inducible HSV-TK in transformed cell populations
JPH10506007A (ja) 機能修飾されたｈｓｖ１−ｔｋ
Vellutini et al. The maedi-visna virus Tat protein induces multiorgan lymphoid hyperplasia in transgenic mice
JPH05505096A (ja) ウィルス感染のトランスジェニック動物モデル
WO1994021111A1 (fr) Mammifere transgenique utilise en tant que modele de maladie
Chang et al. Murine models for the evaluation of anti-HIV strategies
Buzy Transcriptional regulation of HIV-1 gene expression in the central nervous system: A transgenic model
Lee et al. Prospects for Gene Therapy of HIV Infections and AIDS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960423

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000331